



## Author Index for Volume 19

- Abboud M, 110  
Aboulker J-P, 233  
Adams RJ, 110  
Anderson CB, 188  
Anderson S, 249  
Applegate W, 314  
ARNS 005/ACTG 154  
    Trial Group, 233  
Ashley P, 419  
Aubertin J, 233  
Azen SP, 217  
  
Baird-Cox KA, 451  
Baisden CE, 419  
Baker D, 546  
Barton FB, 477  
Bass DC, 499  
Berkowitz K, 217  
Berman B, 110  
Bigger JT Jr, 1  
Bittner V, 391  
Black HR, 370  
Blank J, 25  
Blot WJ, 352  
Boggs SR, 297  
Boudes Pol, 257  
Bowen D, 461, 606  
Brambilla D, 110  
Briançon S, 336  
Brown LM, 352  
Bryant J, 577  
Buchanan TA, 217  
Bush T, 314  
Bycott PW, 557  
Bzoch KR, 297  
  
Capelozza Filho L, 297  
Carl E, 110  
Chan W, 391  
Chang Y-S, 352  
Charreau I, 233  
Chêne G, 233  
Chuang-Stein C, 167  
Connell JE, 525  
Connor PB, 39  
CONVINCE Research  
    Group, 370  
Cool VA, 451  
Cummings C, 419  
  
Cure J, 110  
Dailey M, 606  
Davis CE, 477  
Davis CS, 178  
Day S, 15  
de Souza Freitas JA, 297  
de Souza TV, 297  
Demakis J, 134  
Dequae L, 233  
Deupree RH, 404  
Deykin D, 134  
Diener-West M, 39  
Dignam JJ, 577  
Dixon-Wood V, 297  
Donfield SM, 451  
Driscoll C, 110  
Dulberg E, 391  
Dupont WD, 591  
  
Egan DA, 1  
Eghtesady P, 198  
Ellenberg SS, 530  
Elliott WJ, 370  
Erblund ML, 404  
Espeland MA, 606  
  
Fairweather WR, 477  
Fakouhi TD, 370  
Favier A, 336  
Fayers P, 15  
Feldman HA, 391  
Feniman MB, 297  
Fihm SD, 134  
Files B, 110  
Fisher B, 577  
Fouad M, 461  
Fraumeni JF Jr, 352  
Friedman L, 523  
Furberg C, 314  
  
Gail MH, 352  
Galan P, 336  
Gallagher D, 110  
Garla LA, 297  
Gent M, 535  
George SL, 477  
George V, 461  
Gergen P, 546  
  
Glass A, 25  
Goff DC, 391  
Goldberg IA, 451  
Goyal N, 159  
Graciano MI, 297  
Grady D, 314  
Grambsch P, 370  
Grandits G, 370  
Green SB, 427  
Grimm RH Jr, 370  
Groves FD, 352  
Guedes de Azevedo Bento  
    Gonçalves C, 297  
  
Hafner R, 233  
Hagner S, 110  
Hansson L, 370  
Harland R, 159  
Harvey D, 15  
Hauck WW, 249  
Hawk SM, 451  
Hawkins BS, 39  
Heinrich JP, 352  
Hemophilia Growth and  
    Development  
        Study, 451  
Hemsell DL, 499  
Henderson WG, 134  
Hendrix SL, 499  
Hercberg S, 336  
Herndon JE II, 440  
HERS Research Group,  
    314  
Hillis A, 419  
Hoel LN, 451  
Holley RL, 499  
Honohan T, 477  
Hornberger J, 198  
Hsu L, 110  
Hu J, 352  
Hu W, 56  
Hulley SB, 314  
Hurlet A, 110  
  
IONDT Research Group,  
    276  
James KE, 131  
Jin M-L, 352



## Author Index for Volume 19

- Abboud M, 110  
Aboulker J-P, 233  
Adams RJ, 110  
Anderson CB, 188  
Anderson S, 249  
Applegate W, 314  
ARNS 005/ACTG 154  
    Trial Group, 233  
Ashley P, 419  
Aubertin J, 233  
Azen SP, 217  
  
Baird-Cox KA, 451  
Baisden CE, 419  
Baker D, 546  
Barton FB, 477  
Bass DC, 499  
Berkowitz K, 217  
Berman B, 110  
Bigger JT Jr, 1  
Bittner V, 391  
Black HR, 370  
Blank J, 25  
Blot WJ, 352  
Boggs SR, 297  
Boudes Pol, 257  
Bowen D, 461, 606  
Brambilla D, 110  
Briançon S, 336  
Brown LM, 352  
Bryant J, 577  
Buchanan TA, 217  
Bush T, 314  
Bycott PW, 557  
Bzoch KR, 297  
  
Capelozza Filho L, 297  
Carl E, 110  
Chan W, 391  
Chang Y-S, 352  
Charreau I, 233  
Chêne G, 233  
Chuang-Stein C, 167  
Connell JE, 525  
Connor PB, 39  
CONVINCE Research  
    Group, 370  
Cool VA, 451  
Cummings C, 419  
  
Cure J, 110  
Dailey M, 606  
Davis CE, 477  
Davis CS, 178  
Day S, 15  
de Souza Freitas JA, 297  
de Souza TV, 297  
Demakis J, 134  
Dequae L, 233  
Deupree RH, 404  
Deykin D, 134  
Diener-West M, 39  
Dignam JJ, 577  
Dixon-Wood V, 297  
Donfield SM, 451  
Driscoll C, 110  
Dulberg E, 391  
Dupont WD, 591  
  
Egan DA, 1  
Eghtesady P, 198  
Ellenberg SS, 530  
Elliott WJ, 370  
Erblund ML, 404  
Espeland MA, 606  
  
Fairweather WR, 477  
Fakouhi TD, 370  
Favier A, 336  
Fayers P, 15  
Feldman HA, 391  
Feniman MB, 297  
Fihm SD, 134  
Files B, 110  
Fisher B, 577  
Fouad M, 461  
Fraumeni JF Jr, 352  
Friedman L, 523  
Furberg C, 314  
  
Gail MH, 352  
Galan P, 336  
Gallagher D, 110  
Garla LA, 297  
Gent M, 535  
George SL, 477  
George V, 461  
Gergen P, 546  
  
Glass A, 25  
Goff DC, 391  
Goldberg IA, 451  
Goyal N, 159  
Graciano MI, 297  
Grady D, 314  
Grambsch P, 370  
Grandits G, 370  
Green SB, 427  
Grimm RH Jr, 370  
Groves FD, 352  
Guedes de Azevedo Bento  
    Gonçalves C, 297  
  
Hafner R, 233  
Hagner S, 110  
Hansson L, 370  
Harland R, 159  
Harvey D, 15  
Hauck WW, 249  
Hawk SM, 451  
Hawkins BS, 39  
Heinrich JP, 352  
Hemophilia Growth and  
    Development  
        Study, 451  
Hemsell DL, 499  
Henderson WG, 134  
Hendrix SL, 499  
Hercberg S, 336  
Herndon JE II, 440  
HERS Research Group,  
    314  
Hillis A, 419  
Hoel LN, 451  
Holley RL, 499  
Honohan T, 477  
Hornberger J, 198  
Hsu L, 110  
Hu J, 352  
Hu W, 56  
Hulley SB, 314  
Hurlet A, 110  
  
IONDT Research Group,  
    276  
James KE, 131  
Jin M-L, 352

- Jones BN, 606  
 Jorge JC, 297  
 Joseph C, 546
- Karrison TG, 430  
 Kelsey SF, 499  
 Kemker J, 297  
 Kjos S, 217  
 Knatterud GL, 477, 537  
 Kupfer C, 539  
 Kutlar A, 110
- Lachenbruch PA, 571  
 Lacouière Y, 370  
 Lave JR, 499  
 Lazarini Marques I, 297  
 Leber PD, 178  
 Lenfant C, 523  
 Leport C, 233  
 Levin B, 1  
 Lewin J, 110  
 Lewis CE, 461  
 Li J-Y, 352  
 Liu W-D, 352  
 Luft B, 233
- Ma J-L, 352  
 Machado Neto JS, 297  
 Maeder MA, 451  
 Mahoney EM, 451  
 Malvy D, 336  
 Manheim LM, 149  
 Mann NC, 391  
 Marcus SM, 249  
 Mark SD, 352  
 Marks R, 297  
 McBee WL, 606  
 McGovern PG, 391  
 McKie VC, 110  
 McNiff Mortimer K, 546  
 Meier P, 1  
 Meinert CL, 515, 541  
 Menezes Cardoso  
     Martinelli AP, 297  
 Miller S, 110  
 Mitchell H, 546  
 Montagnoli LC, 297  
 Morlat P, 233  
 Morwey R, 477  
 Muller J, 370  
 Muniz Pimentel  
     Chinellato MC,  
     297  
 Murray DM, 391
- Nackashi AJ, 297  
 Neaton JD, 370, 525  
 Ness RB, 499  
 Neuhauser DB, 427  
 Newhouse MM, 39  
 Nichols FT, 110  
 Niewoehner DE, 404  
 Nova Silva ML, 297
- O'Neill R, 477  
 Ober C, 430  
 Oddone E, 134  
 Olivier N, 110  
 Overall JE, 188
- Parides MK, 1  
 PEACH Study  
     Investigators, 499  
 Pearson SK, 451  
 Pegelow C, 110  
 Pegoraro-Krook MI, 297  
 Peipert J, 499  
 Pereira Lauris JR, 297  
 Peters RK, 217  
 Piazzentini SH, 297  
 Plummer WD, 591  
 Porter V, 461  
 Preziosi P, 336  
 Prouschon MA, 391
- Rabkin CS, 352  
 Rajab MH, 419  
 Randall H, 499  
 Rapp SR, 606  
 REACT Study Group, 391  
 Reboussin BA, 606  
 Rees R, 159  
 Richard SK, 451  
 Riggs B, 314  
 Roach S, 110  
 Rockhold FW, 477  
 Rolnitsky LM, 1  
 Roussel A-M, 336
- Salamon R, 233  
 SCCOPE Study Group,  
     404  
 Scher C, 110  
 Seagle MB, 297  
 Senturia YD, 546  
 Shobaki G, 188  
 Shumaker SA, 606  
 Shuster JJ, 269
- Sirois PA, 451  
 Sleight P, 370  
 Sondeiner SJ, 499  
 Songer TJ, 499  
 Soper DE, 499  
 Stylianou M, 391  
 Sweet RL, 499
- Taylor JMG, 557  
 Terrell T, 606  
 Tighe F, 110  
 Triol I, 336  
 TRIPOD Study Group, 217
- Urban N, 461
- Valanis B, 25  
 Veatch RM, 533  
 Vichinsky E, 110  
 Vickers A, 159  
 Vilde J-L, 233  
 Villamaria FJ, 419
- Waclawiw MA, 110  
 Wang W, 110  
 Weber MA, 370  
 Wedner HJ, 546  
 Weinberger M, 134  
 Weinmann G, 523  
 Wharton W, 297  
 WHIMS Investigators, 606  
 White WB, 370  
 WHT:FSMP Investigators  
     Group, 461  
 Wieand HS, 577  
 Williams G, 370  
 Williams WN, 297  
 Wittes J, 313, 370  
 Wolmark N, 577  
 Women's Health Initiative  
     Study Group, 61  
 Woods G, 110  
 Wright E, 110
- Xiang A, 217  
 Xu G-W, 352
- You W-C, 352
- Zanchetti A, 370  
 Zhang J, 56  
 Zhang L, 352  
 Zimmerman MC, 297  
 Zimmerman RA, 110



## Subject Index for Volume 19

### ACTG PROTOCOL 019

An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

### ACUPUNCTURE

Do Certain Countries Produce Only Positive Results? A Systematic Review of Controlled Trials, 159

### ADNEXITIS

Design of a PID Evaluation and Clinical Health (PEACH) Study, 499

### AGE AT SURGERY

A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

### AGING

The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

### ALZHEIMER'S DISEASE

The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

### ANTIOXIDANTS

A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336

### ARRHYTHMIA

Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1

### ASCORBIC ACID

Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

### ATENOLOL

Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, 370

### AUDITING

Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477

### BAYESIAN METHODS

Bayesian Biostatistics (book review), 271  
Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

### BINOMIAL MODELS

Single or Double Data Entry: Considerations Based on a Simple Binomial Model (letter), 56

### BIOSTATISTICS

Bayesian Biostatistics (book review), 271

### BREAST CANCER

Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

**CALCIUM AND VITAMIN D SUPPLEMENTATION**

Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

**CALCIUM ANTAGONISTS**

Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, 370

**CANCER**

A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials, 440

A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336

Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461

**CARDIOVASCULAR DISEASES**

A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336

Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461

**CARRY-OVER EFFECT**

Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection, 178

**CD4 T CELLS**

An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

**Comparability of Absolute/Percent**

CD4+ T-Lymphocytes Completed Locally and Centrally, 451

**CENTRAL LABORATORY**

Comparability of Absolute/Percent CD4+ T-Lymphocytes Completed Locally and Centrally, 451

**CEREBRAL HEMORRHAGE**

Stroke Prevention Trial in Sickle Cell Anemia, 110

**CHILDREN/PEDIATRIC**

Stroke Prevention Trial in Sickle Cell Anemia, 110

Successful Techniques for Retention of Study Participants in an Inner-City Population, 546

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): Rationale and Design of an Equivalence Trial, 404

**CIRCADIAN VARIATION**

Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, 370

**CLEFT LIP AND PALATE**

A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

**CLINICAL RESEARCH**

Efficient Clinical Research (editorial), 427

**COGNITIVE IMPAIRMENT**

The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

**COHORT STUDY**

- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61  
 Successful Techniques for Retention of Study Participants in an Inner-City Population, 546

**COMMUNITY TRIAL DESIGN**

- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

**COMPLIANCE**

- Drug Compliance in Therapeutic Trials: A Review, 257

**CORONARY ARTERY BYPASS SURGERY**

- Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1

**CORONARY HEART DISEASE**

- Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314

**CORTICOSTEROIDS**

- Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): Rationale and Design of an Equivalence Trial, 404

**COST EFFECTIVENESS**

- Cost-effectiveness in Health and Medicine (book review), 214  
 Health Services Research Clinical Trials: Issues in the Evaluation of Economic Costs and Benefits, 149  
 The Cost-Benefit of a Randomized Trial to a Health Care Organization, 198

**COST EVALUATION**

- Health Services Clinical Trials: Design, Conduct, and Cost Methodology, 131  
 Health Services Research Clinical Trials: Issues in the Evaluation of Economic Costs and Benefits, 149

**COX REGRESSION**

- Should We Adjust for Covariates in Nonlinear Regression Analyses of Randomized Trials, 249  
 An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

**DATA INTEGRITY**

- Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477

**DATA MANAGEMENT**

- Double Data Entry: What Value, What Price?, 15

**DATA MONITORING**

- Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

**DATA VERIFICATION**

- Double Data Entry: What Value, What Price?, 15  
 Feasibility of Keying Data from Screen-Displayed Facsimile Images in an Ongoing Trial: The Collaborative Ocular Melanoma Study, 39

**DECISION ANALYSIS**

- Prevention Effectiveness: Guide to Decision Analysis and Economic Evaluation (book review), 212  
 The Cost-Benefit of a Randomized Trial to a Health Care Organization, 198

**DEMENTIA**

- The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

**DESIGN OF CLINICAL TRIALS**

- A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials, 440  
 A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function

- for Speech Following Palatal Surgery, 297
- A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336
- Cooperative Studies in Health Services Research in the Department of Veterans Affairs, 134
- Design of a PID Evaluation and Clinical Health (PEACH) Study, 499
- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352
- Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314
- Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, 370
- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391
- Stroke Prevention Trial in Sickle Cell Anemia, 110
- Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): Rationale and Design of an Equivalence Trial, 404
- The Design and Analysis of Sequential Clinical Trials* (book review), 604
- The Ischemic Optic Neuropathy Decompression Trial: (IONDT): Design and Methods, 276
- TRIPOD (TRoglitazone in the Prevention of Diabetes): A Randomized, Placebo-controlled Trial of Troglitazone in Women With Prior Gestational Diabetes Mellitus, 217
- DIABETES**
- TRIPOD (TRoglitazone in the Prevention of Diabetes): A Randomized, Placebo-controlled Trial of Troglitazone in Women With Prior Gestational Diabetes Mellitus, 217
- Troglitazone in Women With Prior Gestational Diabetes Mellitus, 217
- DIETARY MODIFICATION**
- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
- DISEASE PREVENTION**
- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
- DOUBLE DATA ENTRY**
- Double Data Entry: What Value, What Price?, 15
- Feasibility of Keying Data from Screen-Displayed Facsimile Images in an Ongoing Trial: The Collaborative Ocular Melanoma Study, 39
- Single or Double Data Entry: Considerations Based on a Simple Binomial Model (letter), 56
- DRUG DEVELOPMENT**
- Drug Compliance in Therapeutic Trials: A Review, 257
- Statistical Issues in Drug Development* (book review), 494
- ECONOMIC EVALUATION**
- Prevention Effectiveness: Guide to Decision Analysis and Economic Evaluation* (book review), 212
- EFFECTIVENESS STUDIES**
- Three Years of Experience with Prospective Randomized Effectiveness Studies, 419
- EMERGENCY MEDICINE**
- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391
- ENRICHMENT DESIGN**
- Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection, 178
- EQUIVALENCE TRIAL**
- Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease

- Exacerbations (SCCOPE): Rationale and Design of an Equivalence Trial, 404
- ESTROGEN**  
Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314
- The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606
- ETHNICITY**  
Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461
- EXTERNAL COMPARISONS**  
Publishing Clinical Trials and Dealing with External Comparisons (editorial), 269
- EXTERNAL VALIDITY**  
Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection, 178
- FACTORIAL INTERVENTION STUDIES**  
Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352
- FREQUENCY OF MEASUREMENTS**  
Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188
- FURLOW**  
A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297
- GARLIC**  
Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352
- Shandong, China: Design Issues and Initial Data, 352
- GROUP SEQUENTIAL MONITORING**  
Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1
- HEALTH PROMOTION**  
Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391
- HEALTH SERVICES RESEARCH**  
Cooperative Studies in Health Services Research in the Department of Veterans Affairs, 134
- Health Services Clinical Trials: Design, Conduct, and Cost Methodology, 131
- Health Services Research Clinical Trials: Issues in the Evaluation of Economic Costs and Benefits, 149
- HEALTH-CARE DELIVERY**  
Cooperative Studies in Health Services Research in the Department of Veterans Affairs, 134
- HEALTH-CARE ORGANIZATION**  
Cooperative Studies in Health Services Research in the Department of Veterans Affairs, 134
- HELICOBACTER PYLORI**  
Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352
- HIV INFECTION**  
Intent-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients, 233
- HORMONE REPLACEMENT THERAPY**  
Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

**HYDROCHLOROTHIAZIDE**

Rationale and Design for the Controlled  
ONset Verapamil  
INvestigation of Cardiovascular  
Endpoints (CONVINCE) Trial,  
370

**IMAGE-BASED ENTRY**

Feasibility of Keying Data from Screen-  
Displayed Facsimile Images in an  
Ongoing Trial: The Collaborative  
Ocular Melanoma Study, 39

**IMPLANTABLE CARDIAC  
DEFIBRILLATOR**

Changes in Sample Size and Length of  
Follow-up to Maintain Power in  
The Coronary Artery Bypass Graft  
(CABG) Patch Trial, 1

**INFERTILITY**

Design of a PID Evaluation and Clinical  
Health (PEACH) Study, 499

**INTENT-TO-TREAT**

Intent-to-Treat vs. On-Treatment  
Analyses of Clinical Trial Data:  
Experience from a Study of  
Pyrimethamine in the Primary  
Prophylaxis of Toxoplasmosis in  
HIV-Infected Patients, 233  
Recurrent Miscarriage (REMIS) Study:  
How Should Data from Women  
Who Do Not Become Pregnant Be  
Handled?, 430

**INTERLABORATORY VARIATION**

Comparability of Absolute/Percent  
CD4+ T-Lymphocytes  
Completed Locally and  
Centrally, 451

**INTERNAL VALIDITY**

Threats to the Validity of Clinical Trials  
Employing Enrichment  
Strategies for Sample Selection,  
178

**KEY DATA ENTRY**

Feasibility of Keying Data from Screen-  
Displayed Facsimile Images in an  
Ongoing Trial: The Collaborative  
Ocular Melanoma Study, 39

**LABORATORY TOXICITY**

Laboratory Data in Clinical Trials: A  
Statistician's Perspective, 167

**LINEAR MODELS/REGRESSION**

Power and Sample Size Calculation for  
Studies Involving Linear  
Regression, 591

**LINEAR TRENDS**

Comparative Evaluations of Two Models  
for Estimating Sample Sizes for  
Tests on Trends Across Repeated  
Measurements, 188

**LOGISTIC REGRESSION**

Should We Adjust for Covariates in  
Nonlinear Regression Analyses  
of Randomized Trials, 249

**LONGITUDINAL MARKERS**

An Evaluation of a Measure of the  
Proportion of the Treatment  
Effect Explained by a Surrogate  
Marker, 557

**MAGNETIC RESONANCE**

ANGIOGRAPHY/IMAGING  
Stroke Prevention Trial in Sickle Cell  
Anemia, 110

**MANAGED CARE**

Health Services Clinical Trials: Design,  
Conduct, and Cost  
Methodology, 131

**META-ANALYSES**

Do Certain Countries Produce Only  
Positive Results? A Systematic  
Review of Controlled Trials, 159  
Should We Adjust for Covariates in  
Nonlinear Regression Analyses  
of Randomized Trials, 249

**MILLARD METHOD**

A Methodology Report of a Randomized  
Prospective Clinical Trial to  
Assess Velopharyngeal Function  
for Speech Following Palatal  
Surgery, 297

**MINORITIES**

Successful Techniques for Retention of  
Study Participants in an Inner-  
City Population, 546

**MONITORING**

A Discussion of "Clinical Trials and  
Effects Monitoring" by Curtis L.

- Meinert, 523, 525, 528, 530, 535, 537, 539  
Clinical Trials and Treatment Effects Monitoring, 515  
Comments on Commentaries of "Clinical Trials and Effects Monitoring" (response), 541  
Data Safety and Monitoring Committees: Accountable to Subjects and Society, 533  
Design of the Women's Health Initiative Clinical Trial and Observational Study, 61  
Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477
- MULTICENTER TRIALS**  
A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials, 440  
Cooperative Studies in Health Services Research in the Department of Veterans Affairs, 134  
Laboratory Data in Clinical Trials: A Statisticians Perspective, 167  
Mailing Strategies and Costs of Recruiting Heavy Smokers in CARET, a Large Chemoprevention Trial, 25  
Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391
- MULTISTAGE STUDY DESIGN**  
A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials, 440
- OMITTED COVARIATES**  
Should We Adjust for Covariates in Nonlinear Regression Analyses of Randomized Trials, 249
- ON-TREATMENT ANALYSIS**  
Intent-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients, 233
- OPHTHALMOLOGY**  
The Ischemic Optic Neuropathy Decompression Trial: (IONDT): Design and Methods, 276
- OPTIC NEUROPATHY**  
The Ischemic Optic Neuropathy Decompression Trial: (IONDT): Design and Methods, 276
- OUTCOMES**  
Three Years of Experience with Prospective Randomized Effectiveness Studies, 419
- PARTIAL FACTORIAL DESIGN**  
Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
- PEDIATRIC ASTHMA**  
Successful Techniques for Retention of Study Participants in an Inner-City Population, 546
- PELVIC INFLAMMATORY DISEASE**  
Design of a PID Evaluation and Clinical Health (PEACH) Study, 499
- POSTMENOPAUSAL HORMONE THERAPY**  
Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314
- POSTMENOPAUSAL WOMEN**  
Design of the Women's Health Initiative Clinical Trial and Observational Study, 61  
Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314
- POSTRANDOMIZATION EXCLUSIONS**  
Recurrent Miscarriage (REMIS) Study: How Should Data from Women Who Do Not Become Pregnant Be Handled?, 430
- POWER**  
Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1  
Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188

- Power and Sample Size Calculation for Studies Involving Linear Regression, 591**
- Recurrent Miscarriage (REMIS) Study: How Should Data from Women Who Do Not Become Pregnant Be Handled?, 430**
- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391**
- PRECANCEROUS LESIONS**
- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352**
- PREVENTION**
- A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study—Design, Methods, and Participant Characteristics, 336**
- Mailing Strategies and Costs of Recruiting Heavy Smokers in CARET, a Large Chemoprevention Trial, 25**
- Prevention Effectiveness: Guide to Decision Analysis and Economic Evaluation (book review), 212**
- Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461**
- The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606**
- TRIPOD (TRoglitazone in the Prevention of Diabetes): A Randomized, Placebo-controlled Trial of Troglitazone in Women With Prior Gestational Diabetes Mellitus, 217**
- PUBLISHING**
- Do Certain Countries Produce Only Positive Results? A Systematic Review of Controlled Trials, 159**
- Publishing Clinical Trials and Dealing with External Comparisons (editorial), 269**
- QUALITY CONTROL**
- Double Data Entry: What Value, What Price?, 15**
- Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477**
- RANDOM COEFFICIENTS ANALYSIS**
- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391**
- RANDOMIZATION**
- Three Years of Experience with Prospective Randomized Effectiveness Studies, 419**
- RATES OF CHANGE**
- Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188**
- RECRUITMENT**
- Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461**
- REFEREE**
- Publishing Clinical Trials and Dealing with External Comparisons (editorial), 269**
- REFERENCE RANGES**
- Laboratory Data in Clinical Trials: A Statisticians Perspective, 167**
- REGRESSION ANALYSIS**
- Power and Sample Size Calculation for Studies Involving Linear Regression, 591**
- REPEATED MEASUREMENTS**
- Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188**
- RETENTION**
- Successful Techniques for Retention of Study Participants in an Inner-City Population, 546**

**SAFETY**

- Data Safety and Monitoring Committees: Accountable to Subjects and Society, 533  
 Laboratory Data in Clinical Trials: A Statistician's Perspective, 167

**SAMPLE SIZE**

- Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1  
 Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188  
 Power and Sample Size Calculation for Studies Involving Linear Regression, 591  
 The Cost-Benefit of a Randomized Trial to a Health Care Organization, 198

**SCIENTIFIC MISCONDUCT**

- Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477

**SELENIUM**

- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

**SENSITIVITY**

- Sensitivity, Specificity and Vaccine Efficacy, 571

**SICKLE CELL DISEASE**

- Stroke Prevention Trial in Sickle Cell Anemia, 110

**SINGLE DATA ENTRY**

- Double Data Entry: What Value, What Price?, 15  
 Single or Double Data Entry: Considerations Based on a Simple Binomial Model (letter), 56

**SMOKING**

- Mailing Strategies and Costs of Recruiting Heavy Smokers in CARET, a Large Chemoprevention Trial, 25

**SOCIOECONOMIC STATUS**

- Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461

**SPECIFICITY**

- Sensitivity, Specificity and Vaccine Efficacy, 571

**SPEECH OUTCOME**

- A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

**SPINA METHOD**

- A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

**STATISTICS. *see also* Specific methods**

- Power and Sample Size Calculation for Studies Involving Linear Regression, 591  
*Statistical Issues in Drug Development* (book review), 494

**STOCHASTIC CURTAILMENT**

- Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

**STOMACH NEOPLASMS**

- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

**STOPPING RULES**

- Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

**STROKE**

- Stroke Prevention Trial in Sickle Cell Anemia, 110

**STUDY ORGANIZATION AND MANAGEMENT**

- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61  
 Cooperative Studies in Health Services Research in Dept. of Veteran Affairs, 134  
 Design of a PID Evaluation and Clinical Health (PEACH) Study, 499

**SURGERY**

- A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

**SURVEILLANCE STUDIES**

- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

**SURVIVAL ANALYSIS**

- Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1

**TAMOXIFEN**

- Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

**TEST SIZE**

- Recurrent Miscarriage (REMIS) Study: How Should Data from Women Who Do Not Become Pregnant Be Handled?, 430

**TIME-DEPENDENT COX MODEL**

- An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

**TRACE-ELEMENTS**

- A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design,

- Methods, and Participant Characteristics, 336

**TRANSCRANIAL DOPPLER ULTRASOUND**

- Stroke Prevention Trial in Sickle Cell Anemia, 110

**TRANSFUSION**

- Stroke Prevention Trial in Sickle Cell Anemia, 110

**TRIAL MONITORING**

- A Discussion of "Clinical Trials and Effects Monitoring" by Curtis L. Meinert, 523, 525, 528, 530, 535, 537, 539

- Clinical Trials and Treatment Effects Monitoring, 515

- Comments on Commentaries of "Clinical Trials and Effects Monitoring" (rejoinder), 541

- Data Safety and Monitoring Committees: Accountable to Subjects and Society, 533

- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

- Guidelines for Quality Assurance in Multicenter Trials: a Position Paper, 477

**TWO-STAGE ANALYTIC METHODS**

- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

**UNBLINDING**

- Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection, 178

**VACCINE EFFICACY**

- Sensitivity, Specificity and Vaccine Efficacy, 571

**VITAMIN C**

- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

**VITAMIN E**

Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

**VITAMINS**

A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study—Design, Methods, and Participant Characteristics, 336  
Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

**von LANGENBECK PROCEDURE**

A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

**WITHDRAWAL EFFECT**

Threats to the Validity of Clinical Trials Employing Enrichment

**Strategies for Sample Selection,**

178

**WOMEN'S HEALTH**

Design of a PID Evaluation and Clinical Health (PEACH) Study, 499  
Design of the Women's Health Initiative Clinical Trial and Observational Study, 61  
Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577  
Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314  
Intent-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients, 233  
Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461  
The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

